1. Background {#s1}
=============

Colon cancer is a world-wide health problem and‏ the second most lethal cause of cancer-related death‏ both males and females in the world. It afflicts more‏ than 135,000 patients per year in the world with a incidence‏ rate of 9.4% and kills more than 55,000 patients‏ ([@R1]). Colorectal cancer ranks the second among the‏ most tumor incidence death ([@R2]). The incidence of the‏ colorectal cancer is 8.5% of all cancers and may be‏ related to the lifestyle, obesity, drinking, smoking, as‏ well as other factors ([@R3]).‏

The traditional treatment of the colon cancer‏ includes assisting (application or administration)‏ chemotherapeutic agents and surgery, depending on‏ the location of the metastatic growth, however, the‏ current chemotherapeutic agents induce serious side‏ effects and high toxicity, which also increase the risk‏ of death ([@R4]). Chemotherapy is one of the most important‏ treatments for cancer patients. However, the efficacy‏ of the chemotherapeutic drugs is still limited in‏ most solid tumors ([@R5]).

There are more than one thousand different drugs‏ that were found to possess significant anticancer properties‏ ([@R6]). However, there is still continues demand for‏ development of the new anticancer drugs by scientific‏ exploration among a vast variety of synthetic, biological,and natural products ([@R7]).

Natural products have been used as an important‏ source of anti-cancer agent, which is estimated to‏ become the major alternative for reducing the cancer‏ death in the 21st century ([@R6]).

Pro-apoptotic potential of the natural substances‏ has made them candidate against cancer ([@R8]). Plants‏ represent wide variety of phytochemicals with pharmaceutical‏ potential such as poly phenolic, terpenoids,‏ taxol, podophyllum peltatam, and flavonoid compounds.‏ Flavonoids are a class of compound composed‏ of a wide range of plant pigments that are universally‏ present in the fruits and vegetables derived foods. To‏ date more than 4,000 types of biologically active‏ flavonoids have been identified ([@R9]). Chrysin is composed‏ of a large class of polyphenolic compounds‏ present in the diet and many herbal products, which‏ have long been associated with a variety of important‏ biochemical and pharmacological activities in the cancer‏ prevention and health promotion ([@R9],[@R10]).

A number of studies have shown that chrysin has‏ multiple biological activities, such as anti-inflammation,‏ anti-oxidation and anticancer effects ([@R10]). In‏ addition, chrysin has been reported to induce apoptosis‏ in a panel of cancer cell lines, including Hela cervical‏ cancer cells, U937, HL-60, and L1210 leukemia cells.‏ This plant flavonoid was also able to inhibit tumor‏ angiogenesis *in vivo*, which is a key step in cancer cell‏ metastasis ([@R11]). It has been reported that chrysin possess‏ cytotoxic effect on human colon cancer *in vitro* ([@R9]).

The SALL gene family has been found to be‏ involved in tumorigenesis. This gene family is among‏ the most important transcriptional regulators of the‏ stem cells. SALL4 is the most well studied SALL gene‏ associated with the cancer s. Recent studies have‏ shown that SALL4 is an excellent target for assessment‏ of treatment with regard to several types of cancers‏ including, liver, ovarian primitive germ cell, and‏ testicular germ cell tumors ([@R12]). The association‏ between SALL4 and OCT4, NANOG, and SOX2 suggests‏ that SALL4 might be a candidate marker for the‏ metastatic germ cell tumors ([@R13]). SALL4 was highly‏ expressed in several solid tumors such as breast cancer,‏ germ cell tumor, hepato and gastric cancers, as‏ well as colon carcinoma ([@R14]). The role of SALL4 was‏ the focus on carcinogenesis, prevention, treatment of‏ tumor cell lines, and tumor tissues ([@R15]).

Our aim was to investigate the anti-cancer effect of‏ chrysin on CT26 colon cancer cells both *in vitro* and *in vivo*. Furthermore, we were interested in achieving‏ more insights on the role of chrysin through evaluation‏ of the type of cell death it induces in CT26 cells; in‏ addition to examining the expression of sall4 in colon‏ cancer cells under treatment with chrysin, as well.

2. Objectives {#s2}
=============

In order to have a new insight into the mechanistic‏ cytotoxicity of chrysin, the present study was designed‏ to evaluate whether chrysin was cytotoxic against‏ CT26 colon cancer cells via involvement sall4 and caspase‏ dependent pathway.

3. Materials and Methods {#s3}
========================

3.1. Cell Culture {#s3-0-1}
-----------------

CT26 cells were procured from Pasteur Institute‏ (Tehran, Iran). The cells were cultured in RPMI-1640‏ medium, supplemented with 10% (v/v) Fetal Bovine‏ Serum (FBS, Gibco, Scotland), supplemented with the‏ 1% antibiotic and incubated at 37ºC in a humidified‏ atmosphere of 5% CO~2~.

3.2. In vitro Assays {#s3-0-2}
--------------------

### 3.2.1. Cytotoxicity Assay {#s3-0-3}

CT26 cells were seeded in a 96- well plate‏ overnight and treated with various concentrations of‏ chrysin (10, 20, 40, 80, 100, and 200 μg.mL^-1^) for 24‏ h and 48 h, MTT \[3-(4,5-Dimethylthiazol-2-yl)-2,5-‏ Diphenyltetrazolium Bromide\] (5 mg.mL^-1^ in PBS)‏ was then added to the cells and incubated in the dark‏ for 4 h. Finally, DMSO (dimethyl sulfoxide) was‏ added and optical density was measured at 560 nm‏ with an microplate spectrophotometer (epoch from Bio‏ Tack, USA) ([@R16]).

3.3. Morphological Assessments {#s3-0-4}
------------------------------

CT26 cells were treated with various concentrations‏ of chrysin (10, 20, 40, 80, 100, and 200 ‏ μg.mL^-1^)‏ for 48 h and morphological alteration were observed‏ under an inverted microscope (Bio Photonic, Brazil)‏ and photographs were taken.‏

3.4. Apoptosis Evaluation Using PI (Propodium Iodide) Staining {#s3-0-5}
--------------------------------------------------------------

CT26 cells were treated with inhibitory concentrations‏ of chrysin (40 and 80 μg.mL^-1^, respectively) for‏ 48 h. Cells were harvested and washed with PBS.‏ Afterwards, centrifugation was carried out, and the cell‏ pellet was incubated in 500 μL of a hypotonic buffer‏ (500 μg.mL^-1^ PI in 0.1% sodium citrate and 0.1%‏ Triton X-100) overnight at 4°C and flow cytometry‏ was performed using a BDFACS Calibur system‏ (Becton Dickinson, USA) ([@R17]).‏

3.5. Apoptosis Analysis with Annexin V-FITC and Propodium Iodide Method {#s3-0-6}
-----------------------------------------------------------------------

For quantitative evaluation of the chrysin induced‏ apoptosis, Annexin/Propodium Iodide assay (Abcam,‏ UK) was performed according to the manufacture‏ instruction. Briefly, 48 h after treatment, the CT26‏ cells were trypsinized and resuspended in 500 μL of‏ the 1X binding buffer. Thereafter, 5 μL of Annexin-VFITC‏ and 5 μL of Propodium Iodide were added and‏ incubated at room temperature for 5 min, subsequently‏ analysis was conducted using FACSCalibur (Becton‏ Dickinson) flow cytometry ([@R18]).

3.6. Apoptosis Assessment by DAPI Staining {#s3-0-7}
------------------------------------------

The cells (1.5×105) were seeded in the 6-well plate‏ and treated with different concentrations of chrysin for‏ 2 days. The cells were washed twice with PBS, and‏ then DAPI \[2,2'- diphenyL^-1^-picrylhydrazyl\] was‏ added and incubated for 10 min in the dark. Finally the‏ cells were washed twice with PBS, resuspended in 1‏ mL methanol, and the nuclear morphology was‏ observed under a fluorescence microscopy ([@R18]).

3.7. Caspase-3 and Caspase-9 Asctivity {#s3-0-8}
--------------------------------------

In order to detect the induced apoptotic pathway, caspase-9 or caspase-3 colorimetric assay (Abcam-UK) was‏ conducted as per manufacturer's instruction. CT26 cells‏ (2×06) were treated with inhibitory concentrations of‏ chrysin for 48 h. Then cells were harvested and mixed‏ with 50 μL lysis buffer. Subsequently, 50 μL of 2X reaction‏ buffer was added to each cytosolic extract. Finally,‏ 5 μL of DEVD-p-NA (caspase-3 substrate) or LEHDpNA‏ (caspase-9 substrate) were added and the‏ absorbance of samples was read at 405 nm ([@R19]).

3.8. In vitro Assays {#s3-0-9}
--------------------

### 3.8.1. Chrysin Preparation {#s3-0-10}

Chrysin was purchased from Sigma (Cat no. C‏ 80105). To prepare different concentrations of the‏ chrysin (0.5, 1, 2, 4, 8, and 10 mg.kg^-1^), chrysin was‏ dissolved in 100 μL DMSO (Merck, Germany) and‏ was diluted with serum before experiments.

### 3.8.2. Animals {#s3-0-11}

Male BALB/c mice (25±5 g, 6 weeks of age) were purchased‏ from Pasteur Institute of Iran, and were fed with‏ chow diet (Tous, Khorasan). The mice were maintained in‏ standard condition at 25±2ºC, 12 h light/dark cycles with a‏ relative humidity of 55±5% and a 12 h time cycle.

3.9. In vivo Antitumor Assessment {#s3-0-14}
---------------------------------

‏ To create an allograft colon carcinoma model, CT-‏ 26 mouse colon cancer cells (1.5×10^6^ cells in 0.2 mL‏ PBS) were injected subcutaneously into the right flank‏ of BALB/c mice (n=5). After subcutaneous tumor formation‏ (approximately 7 days) the animals were randomly‏ designated into 5 groups of 5 mice.‏

The mice were divided into group I (control, administrated‏ PBS orally duration treatment period) and treatment‏ groups received chrysin dissolved in serum including group‏ II (0.5 mg.kg^-1^ chrysin), group III (1 mg.kg^-1^ chrysin),‏ group IV (2 mg.kg^-1^ chrysin extract), group V (4‏ mg.kg^-1^ chrysin extract), group VI (8 mg.kg^-1^ chrysin),‏ and group VII (10 mg.kg^-1^ chrysin) via oral administration‏ once daily for 2 weeks. The mice were sacrificed at‏ the end of 2 week and the tumors were removed, then‏ fresh tumors immediately were kept in an RNAlater‏ solution (Qiagen, Hilden, Germany) at -20ºC until‏ extraction.

3.10. Total RNA Extraction, cDNA Synthesis, and Quantitative RT-PCR {#s3-0-12}
-------------------------------------------------------------------

The untreated and treated tumor tissues were snap‏ frozen in the liquid nitrogen, ground mechanically to a‏ fine powder, and were placed in the new cryogenic‏ tubes. Then, RNA was extracted from colon tissue‏ samples using the RNeasy kit according to manufacturer's‏ instruction (Denazist, IRAN), cDNA was synthesized‏ using cDNA synthesis Kit following to the‏ application of total extracted RNA plus oligo dT‏ (Oligo(dT))~12-18~ Primer is suitable for use in firststrand‏ cDNA synthesis with reverse transcriptase. The‏ primer hybridizes to the poly(A) tail of mRNA. It is‏ phosphorylated on the 5´ end to facilitate cloning of‏ cDNA) as primers for the synthesis of the first-strand‏ (Parstous, IRAN) as per manufacturer's protocols.‏

Briefly, cDNA synthesize was performed in the presence‏ of random hexamer or oligo dT, then incubated at‏ 65ºC for 5 min, and followed by addition RT pre-mix,‏ incubation at 25ºC for 10 min, 50ºC for 60 min and 70ºC‏ for 10 min. PCR reaction was performed in a final volume‏ of 20 μL containing: 10 μL Taq pre mix, 2 μL‏ cDNA, 2 μL primer (forward and reverse) and water to‏ a final volume of 20 μL. The sequences of primers used‏ in this study were as follows: GAPDH (Glyceral‏ dehyde 3-phosphate dehydrogenase) Forward 5´-AGATGGTGAAAGTCGGAGTCA-3´, Reverse 5´-ATCA‏ TTGATGGCCACCACTTG-3´ was used as the housekeeping‏ gene. The forward and reverse primer for Bax‏ were designed as 5´-TTTGCTTCAGGGTTTCATCCA-3´ and 5´-CTCCATGTTACTGTCCAGTTCGT-3´, forward‏ and reverse primer for sall4 were as follow 5´-‏ CCAAAGGCAACTTAAAGGTTCAC-3´ and 5´-CCGTG‏ AAGACCAATGAGATCTC-3´. Following to the amplification,‏ the PCR products were electrophoresed in a‏ 2% agarose gel and were evaluated by green viewer‏ staining ([@R20]).

3.11. Statistical Analysis {#s3-0-13}
--------------------------

Our data were expressed as means±SD. Analysis of‏ variance and significant differences were obtained by‏ SPSS 16 software, one-way ANOVA analysis. Values‏ of the *P*\<0.05 were considered as significant.

4. Results {#s4}
==========

4.1. Effect of Chrysin on CT26 Cell Proliferation {#s4-0-1}
-------------------------------------------------

To determine the cytotoxic effect of chrysin, colon‏ cancer were treated with different concentrations of the‏ chrysin ranging from 10 to 200 μg.mL^-1^ for 24 and 48 h.‏ ([Figure 1](#F1){ref-type="fig"}) shows that chrysin treatment inhibited CT26‏ cell proliferation as a dose dependent manner. The‏ growth rate of CT26 cells in response to 80 μg.mL^-1^ was‏ 48.75% and 46.68% at 24 h and 48 h, respectively. The‏ IC50 for chrysin was determined to be approximately 80‏ μg.mL^-1^ which reduced CT26 cells' growth up to 50%‏ compared to the untreated cells.

![](ijb-14-177-g001){#F1}

4.2. Morphological Studies by Inverted and Fluorescence Microscope {#s4-0-2}
------------------------------------------------------------------

DAPI staining is a reliable apoptotic assay in‏ chemoprevention studies and it helps to observe the‏ apoptotic changes at DNA level. As exhibited in‏ ([Figure 2A](#F2){ref-type="fig"}), specific concentration of chrysin has‏ induced apparent apoptotic morphological alterations,‏ such as a reduction of cell volume, cell shrinkage, and‏ apoptotic body formation in CT26 colon cancer cells‏ showing that apoptosis has been triggered under exposure‏ with growth inhibitory concentration of the‏ chrysin. DAPI staining showed that chrysin has‏ induced chromatin condensation as a typical apoptotic‏ feature in the inhibitory concentrations of chrysin‏ ([Figure 2B](#F2){ref-type="fig"}).
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4.3. Detection of Apoptosis by PI Flow Cytometry {#s4-0-3}
------------------------------------------------

The apoptosis inducing effect of the chrysin was‏ analyzed using flow cytometry according to the exclusion‏ of PI by viable cells. As shown in the ([Figure‏ 3A](#F3){ref-type="fig"}), chrysin treatment has significantly increased the‏ sub-G1 peak, which is an indicator of apoptosis induction‏ resulted from DNA fragmentation, and endonuclease‏ activation that is considered as a crucial anti-proliferative‏ mechanism of chrysin treatment.

4.4. AnnexinV FITC Assay {#s4-0-4}
------------------------

The apoptotic alterations of the plasma membrane can‏ be perceived through Annexin V-FITC (Fluorescein isothiocyanate)‏ staining ([@R18]). To verify the apoptotic morphological‏ changes as a result of treatment with chrysin (80‏ μg.mL^-1^), annexin V-FITC/PI staining was performed.‏ Flow cytometry diagrams determined that the percentage‏ of annexin positive cells were gradually increased as the‏ concentration of the chrysin was increased; from the live‏ cells, to an early apoptotic, the late apoptotic, as well as‏ necrotic cell death where it enhanced remarkably. Hence,‏ the percentage of apoptotic cells was 0.7% in the control‏ group, 77.2% in 80 μg.mL^-1^ and 85.7% in 100 μg.mL^-1^‏ treated groups, which is the hallmark of apoptosis induction‏ under treatment with IC50 concentration of the‏ chrysin on CT26 colon tumor cells ([Figure 3B](#F3){ref-type="fig"}).
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4.5. Determination of the Type of Apoptotic Pathway Induced by Caspase -3 and -9 Assay {#s4-0-5}
--------------------------------------------------------------------------------------

To determine the type of apoptotic pathway involved, the level of caspase -3 and -9 were calculated‏ colorimetrically. Our results elucidated that cytotoxic‏ effect of chrysin administrated through an increase in‏ the caspase-3 and caspase-9 activity in the treated cells‏ in a concentration-dependent manner as compared with‏ the control cells. Therefore, it could be concluded that‏ chrysin exerted its cytotoxicity effects on the CT26‏ colon cancer cells via intrinsic apoptotic pathway‏ ([Figure 4](#F4){ref-type="fig"}).
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4.6. Effect of Chrysin on the Tumor Volume {#s4-0-6}
------------------------------------------

As was shown, chrysin suppresses tumor cell‏ growth. We have further investigated its antitumor‏ effects in a mouse model of the colon cancer. As it is‏ shown in ([Figure 5A](#F5){ref-type="fig"}), at the terminalexperiment, the‏ oral administration of chrysin at 8 and 10 mg.kg^-1^ has‏ led to a significant regression in the tumors' volume as‏ compared to the control group treated with the vehicle‏ solution (i.e. PBS).
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4.7. Effect of Chrysin on Sall4 and Bax mRNA Expression in vivo {#s4-0-7}
---------------------------------------------------------------

To investigate the involvement of Bax in the induction‏ of apoptosis *in vivo* in the CT26 colon cancer cells,‏ cells were treated with 50% inhibitory concentrations of‏ chrysin, then expression of Bax family as proapoptotic‏ factors was assessed using RT-PCR. [Figure 5B](#F5){ref-type="fig"} shows‏ that chrysin has up-regulated the level of Bax in a dose‏ dependent manner. As well, analysis of sall4 transcriptional‏ levels showed that treatment with chrysin has‏ down regulated sall4 mRNA level dose dependently in‏ colon cancer cells.

5. Discussion {#s5}
=============

In our study, the anticancer efficacy of the chrysin‏ against CT26 colon cancer cells was investigated. Our‏ observation revealed that chrysin possess moderate‏ cytotoxic effect on CT26 cells in a concentration‏ dependent manner. In addition, the findings from fluorescence‏ microscopy, Annexin-PI and caspase assays‏ showed that the cytotoxicity of chrysin was related to‏ the recruitment of the intrinsic pathway of apoptosis‏ cell death.

Natural products have been used as an alternative‏ medicine from the ancient time and plant-derived compounds‏ were considered as the safe modalities that‏ offer multitude benefits for preventing chronic diseases‏ such as cancer ([@R21],[@R22]). Chrysin is a natural‏ flavonoid presented in many plant extracts, including‏ blue passion flower (*Passiflora caerulea*), honey, and‏ propolis ([@R23]). It is a natural, biologically active compound‏ that possesses potent anti-inflammatory, anticancer,‏ and antioxidant properties ([@R24]).

The pro apoptotic effect of chrysin has been reported‏ in breast carcinoma, cervical cancer, leukemia, lung‏ cancer (NSCLC), and colon cancer *in vitro* ([@R9]). A study‏ by Zhang *et al*. has demonstrated that chrysin and‏ tetraethyl bis-phosphoric ester (one of chrysin derivatives)‏ exhibited potential anti-cancer effects in human‏ cervical carcinoma cells ([@R25]).

The survey carried out by Shao *et al*. has revealed‏ that chrysin induced growth inhibition and apoptosis in‏ the cultured lung cancer; the A549 cells, along with activation‏ of AMP-activated protein kinase (AMPK) ([@R26]).‏ Recently, a synergism between doxorubicin and chrysin‏ administrated cancer cell death has been shown through‏ chemosensitizing these cells to chemotherapy via GSH‏ depletion in the cancer cells ([@R27]).

In this study, we have investigated the anti-cancer‏ effect of chrysin against colon cancer cells *in vivo*.‏ CT26 cell line was injected subcutaneously into mice‏ for allograft colon cancer model formation and assessment‏ of the anti-cancer efficacy of chrysin against colon‏ cancer. The tumor volume measurement has indicated‏ that chrysin (i.e., 4, 8, 10 mg.kg^-1^) dose dependently‏ reduces the tumor volume. In the present study we‏ attempted to further address the anti-cancer potential‏ of chrysin and the involved molecular mechanisms.‏ The *in vivo* results confirmed that regression of mouse‏ CT26 tumor volume under exposure to chrysin was‏ associated with apoptotic death via up regulation of‏ Bax mRNA level in concentration of 10 mg.kg^-1^.‏

The anti-cancer potential of chrysin has also been‏ reported in a variety of cell lines ([@R28]) and animals ([@R29]).‏ Other previous studies have shown that chrysin sensitizes‏ apoptosis induced cell death by tumor necrosis‏ factor (TNF), or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in various human cancer‏ cells ([@R30]), suggesting the therapeutic potential of the‏ chrysin for treatment of human cancers. Izuta and his‏ colleagues have found that chrysin triggers caspase-3‏ activation, mitochondrial membrane depolarization‏ and mitochondrial cytochrome c release ([@R31]).

Pal-Bhadra and coworkers have shown the effect of‏ chrysin and its analogues on cell viability and cell‏ cycle analysis by MTT assay and flow cytometry.‏ They elucidated that chrysin possess potent *in vitro* anti-cancer activity via suppression of the cell proliferation,‏ induction G1 cell cycle arrest, along with the up‏ regulation of p21, in addition to reduction of cyclin D1‏ and Cdk2 protein levels ([@R32]).‏

Associated with the analysis of sall4 expression; in‏ most human malignancies, SALL4 might be over‏ expressed and potentially used as a diagnostic marker.‏ Similarly, Cao *et al* have reported the over expression‏ of SALL4 protein as a novel diagnostic marker for‏ germ cell tumors such as testis and ovary as well as‏ other metastatic germ cells' tumors ([@R33]). Forghani‏ Fard *et al*. (2013) have reported that sall4 is one of the‏ genes involved in the colon carcinogenesis ([@R34]).

A well, in this study we assessed whether anti-cancer‏ effect of chrysin on CT26 cells is associated with‏ sall4 expression or not. Hence, RT-PCR analysis was‏ performed and the mRNA profile of sall4 has demonstrated‏ that chrysin exerts cytotoxicity on CT26 colon‏ tumor cells via down regulation of the sall4 expression.‏ ‏ However, sall4 down regulation could be considered‏ as a palliative marker for treatment of colon cancer.

In conclusion, we have elucidated that chrysin‏ inhibited the proliferation and induced apoptosis in‏ CT26 colon cancer cells and reduction of tumor volume‏ in animal model. Moreover, human clinical trials‏ are necessary to make it clear whether this flavonoid‏ could be proposed as a possible natural agent for the‏ prevention and treatment of the human colon cancer.
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